N-SIDE launches Production App to optimise clinical manufacturing process
The software consulting company claims its software solution has already saved one pharma company €10.5 million
Life sciences software consulting company N-SIDE has launched a Production App which it says will further enhance end-to-end clinical trial supply chain management by optimising the pharmaceutical manufacturing process for entire clinical programmes, from drug substance through to drug product and investigational medicinal product.
The company said that with clinical trial supply chains being notoriously difficult to manage due to constantly changing information and large uncertainty in clinical trial demand, multiple teams and siloed data, the new software solution can solve these challenges by considering "all the manufacturing constraints specific to each clinical manufacturing program to deliver the optimal plan and budget."
According to N-SIDE, the app automatically optimizes the usage of production assets and resources to reduce waste, budget and timelines and then facilitates communication of any changes to all stakeholders, worldwide.
"What-if scenario planning allows teams to understand how individual changes might affect the overall situation and proactively model different scenarios to design the optimal plan," N-SIDE said. "With readily available, accurate data, managers can make informed decisions and rapidly adapt to ever-changing clinical plans."
Explaining the app's capability, the company's Life Sciences Director Sébastien Coppe said the app "connects the dots between the strategic vision and the operational decisions for planning your clinical program manufacturing."
N-SIDE said its app has already been tested by a large pharmaceutical company to optimize the clinical trials manufacturing plan for a key biological compound, resulting in an 11% decrease -- or €10.5-million -- in manufacturing costs.
The company added that with ever-changing supply needs and long manufacturing lead times, it is extremely difficult for clinical managers to plan manufacturing to meet these highly variable needs while also minimizing waste, controlling costs and reducing the risk of disrupted drug supply.
"At a program level, this is particularly challenging as multiple trials need to be considered in different global locations, often with a lack of standardization in ways of working and out-of-date or unreliable data on which to base decisions," N-SIDE said.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance